Phaseline

Companies › Y-mAbs Therapeutics

Y-mAbs Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 24 registered trials: 19 Phase 2, 5 Phase 1; Neurology, Oncology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sargramostim
Granulocyte-macrophage colony-stimulating factor receptor agonist
CSF2RA, CSF2RBPhase 2Neuroblastoma; Bilateral Breast Carcinoma; Neuroblastoma Recurrent; Alzheimer Disease …Apr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03012100SargramostimPhase 2Bilateral Breast CarcinomaOncologyFeb 2025
NCT05754684SargramostimPhase 2Neuroblastoma RecurrentOncologyDec 2025
NCT04902703SargramostimPhase 2Alzheimer DiseaseNeurologyNov 2026
NCT07267234SargramostimPhase 2Solid CancerOncologyDec 2026
NCT01757626SargramostimPhase 1NeuroblastomaOncologyDec 2026
NCT04237623SargramostimPhase 2Transplant-Related Hematologic MalignancyOncologyDec 2026
NCT06173219SargramostimPhase 1Advanced Solid TumorOncologyDec 2026
NCT05817214SargramostimPhase 2Cervical CancerOncologyFeb 2027
NCT01134614SargramostimPhase 2Advanced MelanomaOncologyMar 2027
NCT00669734SargramostimPhase 1Locally Advanced Pancreatic AdenocarcinomaOncologyApr 2027
NCT07078604SargramostimPhase 2Anatomic Stage IV Breast Cancer AJCC v8OncologyApr 2027
NCT05344209SargramostimPhase 2OncologyOncologyJul 2027
NCT02502786SargramostimPhase 2Recurrent OsteosarcomaOncologyJul 2027
NCT04385277SargramostimPhase 2Ganglioneuroblastoma, NodularOncologySep 2027
NCT05242965SargramostimPhase 2Lung Non-Small Cell CarcinomaOncologyNov 2027
NCT03600350SargramostimPhase 2Prostate CancerOncologyDec 2027
NCT06651853SargramostimPhase 2Diffuse Large B-cell LymphomaOncologyDec 2027
NCT03363373SargramostimPhase 2NeuroblastomaOncologyApr 2028
NCT07537400SargramostimPhase 2High-Risk NeuroblastomaOncologyJun 2028
NCT06799026SargramostimPhase 1Multiple MyelomaOncologySep 2028
NCT06528496SargramostimPhase 2High-risk NeuroblastomaOncologyJul 2029
NCT07749365SargramostimPhase 2DLBCL - Diffuse Large B Cell LymphomaOncologyDec 2029
NCT06626516SargramostimPhase 1Metastatic Uveal MelanomaOncologyOct 2030
NCT02339571SargramostimPhase 2Stage III Cutaneous Melanoma AJCC v7OncologyJun 2033

Targets

CSF2RA (1) CSF2RB (1)

Companies with the same targets

–

Companies built like this

CytoDyn CatalYm Alethia Biotherapeutics Abcuro Solstice Oncology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.